Goldman Sachs analyst James Yaro raised the firm’s price target on Lazard (LAZ) to $47 from $44 but keeps a Sell rating on the shares after its Q4 ...
A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...